SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

“During the Phase 2a 5 week PART A

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
F1ash Member Profile
 
Followed By 29
Posts 3,144
Boards Moderated 1
Alias Born 07/16/14
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/19/2017 6:47:52 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/18/2017 9:47:41 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/16/2017 11:07:52 AM
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Pat... "GlobeNewswire Inc." - 10/12/2017 7:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/6/2017 5:18:01 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/5/2017 5:57:37 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/2/2017 7:53:34 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/29/2017 2:33:03 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/26/2017 3:10:51 PM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference "GlobeNewswire Inc." - 9/21/2017 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/20/2017 4:51:51 PM
Biotech's Recently Under the Microscope, Analyst Coverage "InvestorsHub NewsWire" - 9/20/2017 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/19/2017 1:59:44 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/14/2017 2:28:25 PM
Alzheimer’s Disease: Cannabis Formulation Shows Promise "NetworkNewsWire" - 9/12/2017 8:45:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/8/2017 7:21:13 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) "Edgar (US Regulatory)" - 9/7/2017 3:17:45 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/5/2017 2:22:14 PM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX™ 2-73 "GlobeNewswire Inc." - 9/5/2017 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/31/2017 2:46:59 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/29/2017 11:13:56 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/25/2017 2:20:18 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/21/2017 11:43:39 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/18/2017 4:55:37 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/14/2017 5:15:55 PM
F1ash   Thursday, 10/12/17 10:55:52 PM
Re: frrol post# 124394
Post # of 125645 
“During the Phase 2a 5 week PART A only 2 patients discontinued, resulting in a study retention rate of 94%. During the PART B (voluntary extended participation) to date (26 week) only 3 patients discontinued, resulting in a retention rate of 90% for PART B. Overall retention rate at 31 week is 84%.”

“These results closely reflect the practical course of the study where 25% of the patients remained on their initially allocated dose level of 50 mg while 75% of the total number of patients remained in the 30 mg dose level after five weeks of treatment.

Does this poster actually explain what they did?

Is the “low” concentration group made up of 75% from the 50mg group and 25% from the 30 mg group?

http://www.anavex.com/my_uploads/New-Alzheimers-Drug-ANAVEX-2-73-Phase-2A-Study.pdf

The numbesr seem to work.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist